$BMEA

Biomea Fusion, Inc.

Biomea Fusion is a clinical-stage medicines company focused on discovering and developing oral small-molecule drugs for people with diabetes, obesity and other metabolic diseases. Its two core programs are icovamenib, an oral menin inhibitor being studied for type 1 and type 2 diabetes and obesity, and BMF-650, an investigational oral GLP-1 receptor agonist being developed for obesity. Icovamenib is in Phase II studies for type 2 diabetes and a Phase II study for type 1 diabetes; BMF-650 is being evaluated in a Phase I trial. Biomea Fusion conducts research and development, supported by clinical development, operations, pharmacology, regulatory, safety and quality functions. It currently has approximately 40 employees and relies on third parties to manufacture its drug candidates. It has not yet commercialized products, so it does not currently earn money from product sales. The company is headquartered in San Carlos, California.

No enriched coverage for $BMEA in the last 7 days.

No SEC Form 4 filings for $BMEA in the last 30 days.

See all $BMEA insider activity →

HC Wainwright & Co. reiterates Buy rating on Biomea Fusion, $4 price target

HC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.

Citizens reiterates Biomea Fusion stock rating on Phase 1 data

Citizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion (BMEA) after Phase 1 data for BMF-650 showed promising results. The stock trades at $1.26, with analyst targets ranging from $4 to $10. Biomea completed enrollment in a Phase II diabetes trial, with results expected in Q1 2027. Brookline Capital Markets initiated coverage with a Buy rating and $10.00 target. The company canceled a planned public offering due to market conditions.

BMEA sentiment & insider activity

Recent BMEA coverage spans technology, earnings and financial news.

What's driving BMEA

  • Disappointing early‑stage data caused a steep sell‑off.

    benzinga.com · Oct 14, 2026

  • HC Wainwright & Co. reiterated a Buy rating and $4 price target for Biomea Fusion, implying a 217.5% upside from the Oct 13 close. The analyst cited positive clinical trial developments, including promising results from the OPAL study and encouraging Phase 1 data for BMF-650, as reasons for the rating.

    tradingview.com · Oct 14, 2026

  • Positive Phase 1 results and analyst endorsement should drive buying pressure.

    investing.com · Oct 14, 2026

  • Shares fell sharply after the Phase 1 data, indicating market disappointment.

    rttnews.com · Oct 14, 2026

  • Positive early‑stage data may lift the stock as investors anticipate further development.

    SEC EDGAR 8-K · Oct 13, 2026

AlphAI scores every news story that mentions BMEA with an AI model for sentiment and relevance, and aggregates insider trades from Biomea Fusion, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BMEA

Score
$BMEALowAI 8/10

Citizens reiterates Biomea Fusion stock rating on Phase 1 data

Citizens reiterated a Market Outperform rating and $7.00 price target on Biomea Fusion (BMEA) after Phase 1 data for BMF-650 showed promising results. The stock trades at $1.26, with analyst targets ranging from $4 to $10. Biomea completed enrollment in a Phase II diabetes trial, with results expected in Q1 2027. Brookline Capital Markets initiated coverage with a Buy rating and $10.00 target. The company canceled a planned public offering due to market conditions.

$BMEAHighAI 8/10Clinical / regulatory· topline data

Biomea Fusion, Inc. (BMEA): GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026

Biomea Fusion, Inc. (BMEA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026 Legal Disclaimer & Forward-looking Statements Certain statements in this presentation and the accompanying oral commentary are forward

$BMEAMedAI 8/10

Brookline Capital initiates Biomea Fusion stock with buy rating

Brookline Capital initiated coverage on Biomea Fusion (BMEA) with a Buy rating and $10 target, citing undervaluation and strong balance sheet. The company is developing icovamenib for diabetes and BMF-650 for obesity. Two Phase 2 trials for icovamenib in type 2 diabetes are ongoing, with topline results expected in Q1 2027. H.C. Wainwright and Citizens also reiterated Buy ratings with $4 and $7 targets, respectively. Biomea canceled a planned public offering due to unfavorable market conditions.

BMEA Stock Slides As Biomea Fusion Pulls Equity Offering

Biomea Fusion Inc. (BMEA) shares fell 10.77% due to negative sentiment around its clinical trial outlook and a terminated equity offering. The company has no revenue, a net loss of $8.3M, and $35.2M in cash. Analysts note high dilution risk and a bearish trend, with resistance at $1.50 and support at $1.20.

Related tickers